All 1 tracked stories fall under one category: ip-patent. Aprea Therapeutics, Inc. is most often covered alongside ACESOT-1051, which appears in 1 of these 1 story. We currently track 1 Legal story that mention Aprea Therapeutics, Inc., all published on August 29, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Aprea Therapeutics, Inc.
All 1 tracked stories fall under one category: ip-patent. Aprea Therapeutics, Inc. is most often covered alongside ACESOT-1051, which appears in 1 of these 1 story. We currently track 1 Legal story that mention Aprea Therapeutics, Inc., all published on August 29, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Aprea Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Aprea's latest disclosure outlines a multi-jurisdictional patent estate spanning 28 issued and 30 pending patents, with WEE1 filings extending to 2047. The move strengthens exclusivity and signals an aggressive IP-defense strategy in precision oncology.